You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A computational platform to improve the prioritization of drugs and target genes for therapeutic intervention
SBC: Genetic Networks, LLC Topic: 100Project Summary This project proposes further development of a computational discovery platform shown to quantifiably identify and prioritize both targets and compounds for therapeutic intervention, which will accelerate the development of newer, more effective drugs with fewer side-effects. This platform is based on a novel fusion of two state of the art computational approaches (phenolog mapping ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A
SBC: KJ BIOSCIENCES LLC Topic: NIAIDSalmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Air Barrier System for the Prevention of Prosthesis-related Infections
SBC: NIMBIC SYSTEMS, INC. Topic: 300DESCRIPTIONprovided by applicantThis project is an evaluation of a novel devicethe Air Barrier SystemABSto reduce the risk of prosthesisrelated surgical site infection in a multi center clinical trialThe ABS shields surgical incisions intra operatively by creating a field of high purity air surrounding an incision that prevents airborne microorganisms from entering the incisionPreliminary findings ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
An integrated electrical impedance myography platform for neuromuscular disease classification and diagnosis
SBC: MYOLEX, INC. Topic: 103Project SummaryImproved methods for the bedside diagnosis and evaluation of neuromuscular disorders are needed. One technology that is finding increasing use for this purpose is electrical impedance myography (EIM). In EIM, a very weak, high frequency electrical current is passed through a muscle of interest and the resulting surface voltages are measured. Disease associated alterations in the com ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
SBC: Longeveron LLC Topic: NIAAging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomes. Frailty has an overall prevalence of 10% of those 65 years and older, and there is growing awareness in the geriatric community to diagnose and treat this condition, as it is not an inevitable ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
APPSPIRE: expanding the reach of an innovative tobacco control program for youth
SBC: Radiant Creative Group, LLC Topic: NIDADESCRIPTIONprovided by applicantMobile phone technology offers a variety of opportunities for innovative approaches to health communication and interventionThese opportunities have been amplified by the emergence of next generation smartphone devices that are capable of rich multimedia and sophisticated interactivitySmartphone based programs can be integrated seamlessly into a userandapos s daily ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
SBC: Longeveron LLC Topic: NIAThe metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Automated Intestinal Electrical Stimulation for Diabetes
SBC: TRANSTIMULATION RESEARCH INC Topic: 200Diabetes affects more than 9% of Americans and costs over $300 billion in 2017 in USA. Medical therapies have limitations in treating diabetic patients with obesity due their common side effects of weight gain. Bariatric surgery has been proposed for treating diabetic patients with promising outcomes. In this project, we propose a novel method of intestinal electrical stimulation (IES) for treatin ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma
SBC: Altor BioScience, LLC Topic: 102DESCRIPTION provided by applicant Non Hodgkin lymphoma NHL is the most commonly diagnosed hematologic malignancy in the U S with over new cases and about deaths due to NHL expected in Over one third of all cases are slow growing or indolent NHL iNHL which affect older adults and typically present as advanced disease The initial treatment of iNHL consists of an anti CD ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Developing A Novel Therapy for Diabetic Retinopathy
SBC: Charlesson, LLC Topic: WDESCRIPTION provided by applicant Diabetic retinopathy DR is a common complication of diabetes and a leading cause of vision loss in the United States Although the anti vascular endothelial growth factor VEGF drugs have shown impressive efficacies on wet age related macular degeneration AMD they are only effective in approximately of patients with DR likely due to the multi factori ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health